Found 14 hits for monomerid = 451785 Target/Host
(Institution) | Ligand | Target/Host
Links | Ligand
Links | Trg + Lig
Links | Ki
nM | ΔG°
kcal/mole | IC50
nM | Kd
nM | EC50/IC50
nM | koff
s-1 | kon
M-1s-1 | pH | Temp
°C |
|---|
Activin receptor type-1 [172-499]
(Homo sapiens (Human)) | BDBM451785
(US10710980, Example 17 | US10947218, Example 17)Show SMILES Nc1ncc(cc1C(=O)N[C@H]1CC[C@H](O)CC1)-c1ccc(cc1)[C@]12C[C@H]1CN(CCC(F)(F)F)C2 |r,wU:25.27,10.10,wD:23.25,13.14,(-4.76,5.73,;-3.43,4.96,;-2.1,5.73,;-.76,4.96,;-.76,3.42,;-2.1,2.65,;-3.43,3.42,;-4.76,2.65,;-6.1,3.42,;-4.76,1.11,;-6.25,.72,;-6.65,-.77,;-8.14,-1.17,;-9.23,-.08,;-10.72,-.48,;-8.83,1.41,;-7.34,1.81,;.57,2.65,;.57,1.11,;1.9,.34,;3.24,1.11,;3.24,2.65,;1.9,3.42,;4.57,.34,;4.73,1.88,;5.98,.97,;7.01,-.17,;6.24,-1.51,;6.86,-2.91,;8.41,-2.91,;9.18,-4.25,;10.72,-4.25,;8.41,-5.58,;9.57,-5.73,;4.73,-1.19,)| Show InChI InChI=1S/C26H31F3N4O2/c27-26(28,29)9-10-33-14-19-12-25(19,15-33)18-3-1-16(2-4-18)17-11-22(23(30)31-13-17)24(35)32-20-5-7-21(34)8-6-20/h1-4,11,13,19-21,34H,5-10,12,14-15H2,(H2,30,31)(H,32,35)/t19-,20-,21-,25+/m0/s1 | PDB
UniProtKB/SwissProt
GoogleScholar
AffyNet 
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 12 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG
US Patent
| Assay Description
The assays were performed in 384-well, low volume microtiter assay plates in a final reaction volume of 6 ul. Dose-response curves were generated by ... |
US Patent US10710980 (2020)
|
More data for this
Ligand-Target Pair | |
Bone morphogenetic protein receptor type-1A [198-525]
(Homo sapiens (Human)) | BDBM451785
(US10710980, Example 17 | US10947218, Example 17)Show SMILES Nc1ncc(cc1C(=O)N[C@H]1CC[C@H](O)CC1)-c1ccc(cc1)[C@]12C[C@H]1CN(CCC(F)(F)F)C2 |r,wU:25.27,10.10,wD:23.25,13.14,(-4.76,5.73,;-3.43,4.96,;-2.1,5.73,;-.76,4.96,;-.76,3.42,;-2.1,2.65,;-3.43,3.42,;-4.76,2.65,;-6.1,3.42,;-4.76,1.11,;-6.25,.72,;-6.65,-.77,;-8.14,-1.17,;-9.23,-.08,;-10.72,-.48,;-8.83,1.41,;-7.34,1.81,;.57,2.65,;.57,1.11,;1.9,.34,;3.24,1.11,;3.24,2.65,;1.9,3.42,;4.57,.34,;4.73,1.88,;5.98,.97,;7.01,-.17,;6.24,-1.51,;6.86,-2.91,;8.41,-2.91,;9.18,-4.25,;10.72,-4.25,;8.41,-5.58,;9.57,-5.73,;4.73,-1.19,)| Show InChI InChI=1S/C26H31F3N4O2/c27-26(28,29)9-10-33-14-19-12-25(19,15-33)18-3-1-16(2-4-18)17-11-22(23(30)31-13-17)24(35)32-20-5-7-21(34)8-6-20/h1-4,11,13,19-21,34H,5-10,12,14-15H2,(H2,30,31)(H,32,35)/t19-,20-,21-,25+/m0/s1 | UniProtKB/SwissProt
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 2.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG
US Patent
| Assay Description
The assays were performed in 384-well, low volume microtiter assay plates in a final reaction volume of 6 ul. Dose-response curves were generated by ... |
US Patent US10710980 (2020)
|
More data for this
Ligand-Target Pair | |
Activin receptor type-1 [172-499]
(Homo sapiens (Human)) | BDBM451785
(US10710980, Example 17 | US10947218, Example 17)Show SMILES Nc1ncc(cc1C(=O)N[C@H]1CC[C@H](O)CC1)-c1ccc(cc1)[C@]12C[C@H]1CN(CCC(F)(F)F)C2 |r,wU:25.27,10.10,wD:23.25,13.14,(-4.76,5.73,;-3.43,4.96,;-2.1,5.73,;-.76,4.96,;-.76,3.42,;-2.1,2.65,;-3.43,3.42,;-4.76,2.65,;-6.1,3.42,;-4.76,1.11,;-6.25,.72,;-6.65,-.77,;-8.14,-1.17,;-9.23,-.08,;-10.72,-.48,;-8.83,1.41,;-7.34,1.81,;.57,2.65,;.57,1.11,;1.9,.34,;3.24,1.11,;3.24,2.65,;1.9,3.42,;4.57,.34,;4.73,1.88,;5.98,.97,;7.01,-.17,;6.24,-1.51,;6.86,-2.91,;8.41,-2.91,;9.18,-4.25,;10.72,-4.25,;8.41,-5.58,;9.57,-5.73,;4.73,-1.19,)| Show InChI InChI=1S/C26H31F3N4O2/c27-26(28,29)9-10-33-14-19-12-25(19,15-33)18-3-1-16(2-4-18)17-11-22(23(30)31-13-17)24(35)32-20-5-7-21(34)8-6-20/h1-4,11,13,19-21,34H,5-10,12,14-15H2,(H2,30,31)(H,32,35)/t19-,20-,21-,25+/m0/s1 | PDB
UniProtKB/SwissProt
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 14 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG
US Patent
| Assay Description
In the applied method, this separation takes place inside a chip that contains a complex capillary system for simultaneous analysis of 12 samples (“1... |
US Patent US10710980 (2020)
|
More data for this
Ligand-Target Pair | |
Activin receptor type-1 [172-499,R206H]
(Homo sapiens (Human)) | BDBM451785
(US10710980, Example 17 | US10947218, Example 17)Show SMILES Nc1ncc(cc1C(=O)N[C@H]1CC[C@H](O)CC1)-c1ccc(cc1)[C@]12C[C@H]1CN(CCC(F)(F)F)C2 |r,wU:25.27,10.10,wD:23.25,13.14,(-4.76,5.73,;-3.43,4.96,;-2.1,5.73,;-.76,4.96,;-.76,3.42,;-2.1,2.65,;-3.43,3.42,;-4.76,2.65,;-6.1,3.42,;-4.76,1.11,;-6.25,.72,;-6.65,-.77,;-8.14,-1.17,;-9.23,-.08,;-10.72,-.48,;-8.83,1.41,;-7.34,1.81,;.57,2.65,;.57,1.11,;1.9,.34,;3.24,1.11,;3.24,2.65,;1.9,3.42,;4.57,.34,;4.73,1.88,;5.98,.97,;7.01,-.17,;6.24,-1.51,;6.86,-2.91,;8.41,-2.91,;9.18,-4.25,;10.72,-4.25,;8.41,-5.58,;9.57,-5.73,;4.73,-1.19,)| Show InChI InChI=1S/C26H31F3N4O2/c27-26(28,29)9-10-33-14-19-12-25(19,15-33)18-3-1-16(2-4-18)17-11-22(23(30)31-13-17)24(35)32-20-5-7-21(34)8-6-20/h1-4,11,13,19-21,34H,5-10,12,14-15H2,(H2,30,31)(H,32,35)/t19-,20-,21-,25+/m0/s1 | PDB
UniProtKB/SwissProt
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 14 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG
US Patent
| Assay Description
In the applied method, this separation takes place inside a chip that contains a complex capillary system for simultaneous analysis of 12 samples (“1... |
US Patent US10710980 (2020)
|
More data for this
Ligand-Target Pair | |
Serine/threonine-protein kinase receptor R3 [166-493]
(Homo sapiens (Human)) | BDBM451785
(US10710980, Example 17 | US10947218, Example 17)Show SMILES Nc1ncc(cc1C(=O)N[C@H]1CC[C@H](O)CC1)-c1ccc(cc1)[C@]12C[C@H]1CN(CCC(F)(F)F)C2 |r,wU:25.27,10.10,wD:23.25,13.14,(-4.76,5.73,;-3.43,4.96,;-2.1,5.73,;-.76,4.96,;-.76,3.42,;-2.1,2.65,;-3.43,3.42,;-4.76,2.65,;-6.1,3.42,;-4.76,1.11,;-6.25,.72,;-6.65,-.77,;-8.14,-1.17,;-9.23,-.08,;-10.72,-.48,;-8.83,1.41,;-7.34,1.81,;.57,2.65,;.57,1.11,;1.9,.34,;3.24,1.11,;3.24,2.65,;1.9,3.42,;4.57,.34,;4.73,1.88,;5.98,.97,;7.01,-.17,;6.24,-1.51,;6.86,-2.91,;8.41,-2.91,;9.18,-4.25,;10.72,-4.25,;8.41,-5.58,;9.57,-5.73,;4.73,-1.19,)| Show InChI InChI=1S/C26H31F3N4O2/c27-26(28,29)9-10-33-14-19-12-25(19,15-33)18-3-1-16(2-4-18)17-11-22(23(30)31-13-17)24(35)32-20-5-7-21(34)8-6-20/h1-4,11,13,19-21,34H,5-10,12,14-15H2,(H2,30,31)(H,32,35)/t19-,20-,21-,25+/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 110 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG
US Patent
| Assay Description
In the applied method, this separation takes place inside a chip that contains a complex capillary system for simultaneous analysis of 12 samples (“1... |
US Patent US10710980 (2020)
|
More data for this
Ligand-Target Pair | |
TGF-beta receptor type-1 [162-503]
(Homo sapiens (Human)) | BDBM451785
(US10710980, Example 17 | US10947218, Example 17)Show SMILES Nc1ncc(cc1C(=O)N[C@H]1CC[C@H](O)CC1)-c1ccc(cc1)[C@]12C[C@H]1CN(CCC(F)(F)F)C2 |r,wU:25.27,10.10,wD:23.25,13.14,(-4.76,5.73,;-3.43,4.96,;-2.1,5.73,;-.76,4.96,;-.76,3.42,;-2.1,2.65,;-3.43,3.42,;-4.76,2.65,;-6.1,3.42,;-4.76,1.11,;-6.25,.72,;-6.65,-.77,;-8.14,-1.17,;-9.23,-.08,;-10.72,-.48,;-8.83,1.41,;-7.34,1.81,;.57,2.65,;.57,1.11,;1.9,.34,;3.24,1.11,;3.24,2.65,;1.9,3.42,;4.57,.34,;4.73,1.88,;5.98,.97,;7.01,-.17,;6.24,-1.51,;6.86,-2.91,;8.41,-2.91,;9.18,-4.25,;10.72,-4.25,;8.41,-5.58,;9.57,-5.73,;4.73,-1.19,)| Show InChI InChI=1S/C26H31F3N4O2/c27-26(28,29)9-10-33-14-19-12-25(19,15-33)18-3-1-16(2-4-18)17-11-22(23(30)31-13-17)24(35)32-20-5-7-21(34)8-6-20/h1-4,11,13,19-21,34H,5-10,12,14-15H2,(H2,30,31)(H,32,35)/t19-,20-,21-,25+/m0/s1 | PDB
UniProtKB/SwissProt
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 1.60E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG
US Patent
| Assay Description
In the applied method, this separation takes place inside a chip that contains a complex capillary system for simultaneous analysis of 12 samples (“1... |
US Patent US10710980 (2020)
|
More data for this
Ligand-Target Pair | |
Bone morphogenetic protein receptor type-1B
(Homo sapiens (Human)) | BDBM451785
(US10710980, Example 17 | US10947218, Example 17)Show SMILES Nc1ncc(cc1C(=O)N[C@H]1CC[C@H](O)CC1)-c1ccc(cc1)[C@]12C[C@H]1CN(CCC(F)(F)F)C2 |r,wU:25.27,10.10,wD:23.25,13.14,(-4.76,5.73,;-3.43,4.96,;-2.1,5.73,;-.76,4.96,;-.76,3.42,;-2.1,2.65,;-3.43,3.42,;-4.76,2.65,;-6.1,3.42,;-4.76,1.11,;-6.25,.72,;-6.65,-.77,;-8.14,-1.17,;-9.23,-.08,;-10.72,-.48,;-8.83,1.41,;-7.34,1.81,;.57,2.65,;.57,1.11,;1.9,.34,;3.24,1.11,;3.24,2.65,;1.9,3.42,;4.57,.34,;4.73,1.88,;5.98,.97,;7.01,-.17,;6.24,-1.51,;6.86,-2.91,;8.41,-2.91,;9.18,-4.25,;10.72,-4.25,;8.41,-5.58,;9.57,-5.73,;4.73,-1.19,)| Show InChI InChI=1S/C26H31F3N4O2/c27-26(28,29)9-10-33-14-19-12-25(19,15-33)18-3-1-16(2-4-18)17-11-22(23(30)31-13-17)24(35)32-20-5-7-21(34)8-6-20/h1-4,11,13,19-21,34H,5-10,12,14-15H2,(H2,30,31)(H,32,35)/t19-,20-,21-,25+/m0/s1 | PDB
UniProtKB/SwissProt
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 2.40E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
NOVARTIS AG
US Patent
| Assay Description
A kinase selectivity panel which measures substrate peptide phosphorylation was set-up for wild-type ALK2 (aa172-499), ALK2 FOP mutant (aa172-499 R20... |
US Patent US10947218 (2021)
|
More data for this
Ligand-Target Pair | |
Activin receptor type-1 [172-499]
(Homo sapiens (Human)) | BDBM451785
(US10710980, Example 17 | US10947218, Example 17)Show SMILES Nc1ncc(cc1C(=O)N[C@H]1CC[C@H](O)CC1)-c1ccc(cc1)[C@]12C[C@H]1CN(CCC(F)(F)F)C2 |r,wU:25.27,10.10,wD:23.25,13.14,(-4.76,5.73,;-3.43,4.96,;-2.1,5.73,;-.76,4.96,;-.76,3.42,;-2.1,2.65,;-3.43,3.42,;-4.76,2.65,;-6.1,3.42,;-4.76,1.11,;-6.25,.72,;-6.65,-.77,;-8.14,-1.17,;-9.23,-.08,;-10.72,-.48,;-8.83,1.41,;-7.34,1.81,;.57,2.65,;.57,1.11,;1.9,.34,;3.24,1.11,;3.24,2.65,;1.9,3.42,;4.57,.34,;4.73,1.88,;5.98,.97,;7.01,-.17,;6.24,-1.51,;6.86,-2.91,;8.41,-2.91,;9.18,-4.25,;10.72,-4.25,;8.41,-5.58,;9.57,-5.73,;4.73,-1.19,)| Show InChI InChI=1S/C26H31F3N4O2/c27-26(28,29)9-10-33-14-19-12-25(19,15-33)18-3-1-16(2-4-18)17-11-22(23(30)31-13-17)24(35)32-20-5-7-21(34)8-6-20/h1-4,11,13,19-21,34H,5-10,12,14-15H2,(H2,30,31)(H,32,35)/t19-,20-,21-,25+/m0/s1 | PDB
UniProtKB/SwissProt
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 12 | n/a | n/a | n/a | n/a | n/a | n/a |
NOVARTIS AG
US Patent
| Assay Description
A kinase selectivity panel which measures autophosphorylation using the ADP-Glo Kinase Assay (Promega, V9101) was set-up for wild-type ALK2 (aa172-49... |
US Patent US10947218 (2021)
|
More data for this
Ligand-Target Pair | |
Bone morphogenetic protein receptor type-1A [198-525]
(Homo sapiens (Human)) | BDBM451785
(US10710980, Example 17 | US10947218, Example 17)Show SMILES Nc1ncc(cc1C(=O)N[C@H]1CC[C@H](O)CC1)-c1ccc(cc1)[C@]12C[C@H]1CN(CCC(F)(F)F)C2 |r,wU:25.27,10.10,wD:23.25,13.14,(-4.76,5.73,;-3.43,4.96,;-2.1,5.73,;-.76,4.96,;-.76,3.42,;-2.1,2.65,;-3.43,3.42,;-4.76,2.65,;-6.1,3.42,;-4.76,1.11,;-6.25,.72,;-6.65,-.77,;-8.14,-1.17,;-9.23,-.08,;-10.72,-.48,;-8.83,1.41,;-7.34,1.81,;.57,2.65,;.57,1.11,;1.9,.34,;3.24,1.11,;3.24,2.65,;1.9,3.42,;4.57,.34,;4.73,1.88,;5.98,.97,;7.01,-.17,;6.24,-1.51,;6.86,-2.91,;8.41,-2.91,;9.18,-4.25,;10.72,-4.25,;8.41,-5.58,;9.57,-5.73,;4.73,-1.19,)| Show InChI InChI=1S/C26H31F3N4O2/c27-26(28,29)9-10-33-14-19-12-25(19,15-33)18-3-1-16(2-4-18)17-11-22(23(30)31-13-17)24(35)32-20-5-7-21(34)8-6-20/h1-4,11,13,19-21,34H,5-10,12,14-15H2,(H2,30,31)(H,32,35)/t19-,20-,21-,25+/m0/s1 | UniProtKB/SwissProt
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 2.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
NOVARTIS AG
US Patent
| Assay Description
A kinase selectivity panel which measures autophosphorylation using the ADP-Glo Kinase Assay (Promega, V9101) was set-up for wild-type ALK2 (aa172-49... |
US Patent US10947218 (2021)
|
More data for this
Ligand-Target Pair | |
Activin receptor type-1 [172-499]
(Homo sapiens (Human)) | BDBM451785
(US10710980, Example 17 | US10947218, Example 17)Show SMILES Nc1ncc(cc1C(=O)N[C@H]1CC[C@H](O)CC1)-c1ccc(cc1)[C@]12C[C@H]1CN(CCC(F)(F)F)C2 |r,wU:25.27,10.10,wD:23.25,13.14,(-4.76,5.73,;-3.43,4.96,;-2.1,5.73,;-.76,4.96,;-.76,3.42,;-2.1,2.65,;-3.43,3.42,;-4.76,2.65,;-6.1,3.42,;-4.76,1.11,;-6.25,.72,;-6.65,-.77,;-8.14,-1.17,;-9.23,-.08,;-10.72,-.48,;-8.83,1.41,;-7.34,1.81,;.57,2.65,;.57,1.11,;1.9,.34,;3.24,1.11,;3.24,2.65,;1.9,3.42,;4.57,.34,;4.73,1.88,;5.98,.97,;7.01,-.17,;6.24,-1.51,;6.86,-2.91,;8.41,-2.91,;9.18,-4.25,;10.72,-4.25,;8.41,-5.58,;9.57,-5.73,;4.73,-1.19,)| Show InChI InChI=1S/C26H31F3N4O2/c27-26(28,29)9-10-33-14-19-12-25(19,15-33)18-3-1-16(2-4-18)17-11-22(23(30)31-13-17)24(35)32-20-5-7-21(34)8-6-20/h1-4,11,13,19-21,34H,5-10,12,14-15H2,(H2,30,31)(H,32,35)/t19-,20-,21-,25+/m0/s1 | PDB
UniProtKB/SwissProt
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 14 | n/a | n/a | n/a | n/a | n/a | n/a |
NOVARTIS AG
US Patent
| Assay Description
A kinase selectivity panel which measures substrate peptide phosphorylation was set-up for wild-type ALK2 (aa172-499), ALK2 FOP mutant (aa172-499 R20... |
US Patent US10947218 (2021)
|
More data for this
Ligand-Target Pair | |
Activin receptor type-1 [172-499,R206H]
(Homo sapiens (Human)) | BDBM451785
(US10710980, Example 17 | US10947218, Example 17)Show SMILES Nc1ncc(cc1C(=O)N[C@H]1CC[C@H](O)CC1)-c1ccc(cc1)[C@]12C[C@H]1CN(CCC(F)(F)F)C2 |r,wU:25.27,10.10,wD:23.25,13.14,(-4.76,5.73,;-3.43,4.96,;-2.1,5.73,;-.76,4.96,;-.76,3.42,;-2.1,2.65,;-3.43,3.42,;-4.76,2.65,;-6.1,3.42,;-4.76,1.11,;-6.25,.72,;-6.65,-.77,;-8.14,-1.17,;-9.23,-.08,;-10.72,-.48,;-8.83,1.41,;-7.34,1.81,;.57,2.65,;.57,1.11,;1.9,.34,;3.24,1.11,;3.24,2.65,;1.9,3.42,;4.57,.34,;4.73,1.88,;5.98,.97,;7.01,-.17,;6.24,-1.51,;6.86,-2.91,;8.41,-2.91,;9.18,-4.25,;10.72,-4.25,;8.41,-5.58,;9.57,-5.73,;4.73,-1.19,)| Show InChI InChI=1S/C26H31F3N4O2/c27-26(28,29)9-10-33-14-19-12-25(19,15-33)18-3-1-16(2-4-18)17-11-22(23(30)31-13-17)24(35)32-20-5-7-21(34)8-6-20/h1-4,11,13,19-21,34H,5-10,12,14-15H2,(H2,30,31)(H,32,35)/t19-,20-,21-,25+/m0/s1 | PDB
UniProtKB/SwissProt
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 14 | n/a | n/a | n/a | n/a | n/a | n/a |
NOVARTIS AG
US Patent
| Assay Description
A kinase selectivity panel which measures substrate peptide phosphorylation was set-up for wild-type ALK2 (aa172-499), ALK2 FOP mutant (aa172-499 R20... |
US Patent US10947218 (2021)
|
More data for this
Ligand-Target Pair | |
Serine/threonine-protein kinase receptor R3 [166-493]
(Homo sapiens (Human)) | BDBM451785
(US10710980, Example 17 | US10947218, Example 17)Show SMILES Nc1ncc(cc1C(=O)N[C@H]1CC[C@H](O)CC1)-c1ccc(cc1)[C@]12C[C@H]1CN(CCC(F)(F)F)C2 |r,wU:25.27,10.10,wD:23.25,13.14,(-4.76,5.73,;-3.43,4.96,;-2.1,5.73,;-.76,4.96,;-.76,3.42,;-2.1,2.65,;-3.43,3.42,;-4.76,2.65,;-6.1,3.42,;-4.76,1.11,;-6.25,.72,;-6.65,-.77,;-8.14,-1.17,;-9.23,-.08,;-10.72,-.48,;-8.83,1.41,;-7.34,1.81,;.57,2.65,;.57,1.11,;1.9,.34,;3.24,1.11,;3.24,2.65,;1.9,3.42,;4.57,.34,;4.73,1.88,;5.98,.97,;7.01,-.17,;6.24,-1.51,;6.86,-2.91,;8.41,-2.91,;9.18,-4.25,;10.72,-4.25,;8.41,-5.58,;9.57,-5.73,;4.73,-1.19,)| Show InChI InChI=1S/C26H31F3N4O2/c27-26(28,29)9-10-33-14-19-12-25(19,15-33)18-3-1-16(2-4-18)17-11-22(23(30)31-13-17)24(35)32-20-5-7-21(34)8-6-20/h1-4,11,13,19-21,34H,5-10,12,14-15H2,(H2,30,31)(H,32,35)/t19-,20-,21-,25+/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 110 | n/a | n/a | n/a | n/a | n/a | n/a |
NOVARTIS AG
US Patent
| Assay Description
A kinase selectivity panel which measures substrate peptide phosphorylation was set-up for wild-type ALK2 (aa172-499), ALK2 FOP mutant (aa172-499 R20... |
US Patent US10947218 (2021)
|
More data for this
Ligand-Target Pair | |
TGF-beta receptor type-1 [162-503]
(Homo sapiens (Human)) | BDBM451785
(US10710980, Example 17 | US10947218, Example 17)Show SMILES Nc1ncc(cc1C(=O)N[C@H]1CC[C@H](O)CC1)-c1ccc(cc1)[C@]12C[C@H]1CN(CCC(F)(F)F)C2 |r,wU:25.27,10.10,wD:23.25,13.14,(-4.76,5.73,;-3.43,4.96,;-2.1,5.73,;-.76,4.96,;-.76,3.42,;-2.1,2.65,;-3.43,3.42,;-4.76,2.65,;-6.1,3.42,;-4.76,1.11,;-6.25,.72,;-6.65,-.77,;-8.14,-1.17,;-9.23,-.08,;-10.72,-.48,;-8.83,1.41,;-7.34,1.81,;.57,2.65,;.57,1.11,;1.9,.34,;3.24,1.11,;3.24,2.65,;1.9,3.42,;4.57,.34,;4.73,1.88,;5.98,.97,;7.01,-.17,;6.24,-1.51,;6.86,-2.91,;8.41,-2.91,;9.18,-4.25,;10.72,-4.25,;8.41,-5.58,;9.57,-5.73,;4.73,-1.19,)| Show InChI InChI=1S/C26H31F3N4O2/c27-26(28,29)9-10-33-14-19-12-25(19,15-33)18-3-1-16(2-4-18)17-11-22(23(30)31-13-17)24(35)32-20-5-7-21(34)8-6-20/h1-4,11,13,19-21,34H,5-10,12,14-15H2,(H2,30,31)(H,32,35)/t19-,20-,21-,25+/m0/s1 | PDB
UniProtKB/SwissProt
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 1.60E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
NOVARTIS AG
US Patent
| Assay Description
A kinase selectivity panel which measures substrate peptide phosphorylation was set-up for wild-type ALK2 (aa172-499), ALK2 FOP mutant (aa172-499 R20... |
US Patent US10947218 (2021)
|
More data for this
Ligand-Target Pair | |
Bone morphogenetic protein receptor type-1B
(Homo sapiens (Human)) | BDBM451785
(US10710980, Example 17 | US10947218, Example 17)Show SMILES Nc1ncc(cc1C(=O)N[C@H]1CC[C@H](O)CC1)-c1ccc(cc1)[C@]12C[C@H]1CN(CCC(F)(F)F)C2 |r,wU:25.27,10.10,wD:23.25,13.14,(-4.76,5.73,;-3.43,4.96,;-2.1,5.73,;-.76,4.96,;-.76,3.42,;-2.1,2.65,;-3.43,3.42,;-4.76,2.65,;-6.1,3.42,;-4.76,1.11,;-6.25,.72,;-6.65,-.77,;-8.14,-1.17,;-9.23,-.08,;-10.72,-.48,;-8.83,1.41,;-7.34,1.81,;.57,2.65,;.57,1.11,;1.9,.34,;3.24,1.11,;3.24,2.65,;1.9,3.42,;4.57,.34,;4.73,1.88,;5.98,.97,;7.01,-.17,;6.24,-1.51,;6.86,-2.91,;8.41,-2.91,;9.18,-4.25,;10.72,-4.25,;8.41,-5.58,;9.57,-5.73,;4.73,-1.19,)| Show InChI InChI=1S/C26H31F3N4O2/c27-26(28,29)9-10-33-14-19-12-25(19,15-33)18-3-1-16(2-4-18)17-11-22(23(30)31-13-17)24(35)32-20-5-7-21(34)8-6-20/h1-4,11,13,19-21,34H,5-10,12,14-15H2,(H2,30,31)(H,32,35)/t19-,20-,21-,25+/m0/s1 | PDB
UniProtKB/SwissProt
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 2.40E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG
US Patent
| Assay Description
In the applied method, this separation takes place inside a chip that contains a complex capillary system for simultaneous analysis of 12 samples (“1... |
US Patent US10710980 (2020)
|
More data for this
Ligand-Target Pair | |
Search and Browse
